Medios AG Reports Revenue Growth in Q1 2026

Medios AG, a key player in the European Specialty Pharma sector, reported significant revenue growth for Q1 2026. Revenue rose 8.9% to €527.6 million compared to €484.7 million in the same quarter the previous year. Despite an EBITDA pre1 decline of 7.9% to €21.2 million, the company confirms its full-year guidance.

The company's consolidated net income after tax dropped 22.3% to €5.0 million. Earnings per share also fell to €0.20. However, operating cash flow increased dramatically by 250.3% to €12.5 million, attributed to better working capital management.

Medios emphasized expanding higher-margin segments to enhance EBITDA pre1 and margins as the year progresses. Revenue growth was noted across all segments, with the Pharmaceutical Supply segment seeing a 9.0% rise. The company expects full-year revenues between €2.0 billion and €2.12 billion, with the EBITDA pre1 margin potentially increasing to 4.8%.